Inclusion Criteria:

Patients who completed the 10 cycles of docetaxel administrations in the preceding
XRP6976J/2101 study and wish to continue docetaxel administrations,and who have no
alternative therapy for hormone refractory prostate cancer according to the Investigator's
judgment.

Exclusion Criteria:

- Continuation in the study would be detrimental to the patient's well-being

- Development of life-threatening and/or toxic conditions not manageable by symptomatic
care, dose reduction, or delay of dosing

- Obvious disease progression (rising prostate specific antigen, any increase of ≥ 20 %
in the sum of the measurable lesion in comparison to the nadir value, and progression
in non-measurable lesion)

- Patients treated with anti-cancer treatment other than study therapy after completion
of 10 cycles of study treatment in the XRP6976J/2101 study